Individualized five-year risk assessment for oral premalignant lesion progression to cancer

详细信息    查看全文

• 作者：Jason T.K. Hwang ; PhD^a ; ^{Jhwang@proteocyte.com} ; Ying R. Gu ; PhD ; MBA^a ; Mi Shen ; MSc^a ; Ranju Ralhan ; PhD^a ; ^b ; ^c ; ^d ; Paul G. Walfish ; MD ; CM ; O.Ont ; FRCPC ; FCAHS^a ; ^b ; ^c ; ^d ; ^e ; Kenneth P.H. Pritzker ; MD ; FRCPC^a ; ^f ; ^g ; David Mock ; DDS ; PhD ; FRCD(C)^a ; ^h
• 刊名：Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：123
• 期：3
• 页码：374-381
• 全文大小：1427 K
• 卷排序：123

文摘

The standard of care for premalignant lesion risk assessment is dysplasia grading by histopathology. With significant overlap between dysplasia grades and high inter- and intraobserver variations, histopathology dysplasia grading alone is not a useful prognostic tool. Our aim is to investigate whether a method for quantitatively assessing S100A7, a prognostic biomarker, using image analysis can better predict clinical outcome in cases with oral dysplasia.Study DesignUsing the Visiopharm image analysis system, we analyzed a cohort of 150 oral biopsy samples to build and test Straticyte, a model for individualized assessment of the 5-year risk of progression of oral precancerous lesions to invasive squamous cell carcinomas.ResultsStraticyte classified lesions more accurately than histopathological dysplasia grading for risk to progression to cancer over the following 5 years. The sensitivity of low-risk versus intermediate- and high-risk Straticyte groups was 95% compared to 75% for mild versus moderate and severe dysplasia. Furthermore, the negative predictive value for low-risk versus intermediate- and high-risk Straticyte groups was 78% compared to 59% for mild versus moderate and severe dysplasia.ConclusionBy quantitatively assessing S100A7, Straticyte better defines the risk for developing oral squamous cell carcinoma than histopathological dysplasia grading alone.